|
Jul 22
|
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know
|
|
Jul 22
|
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
|
|
Jul 22
|
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
|
|
Jul 22
|
Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment
|
|
Jul 22
|
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?
|
|
Jul 21
|
EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships
|
|
Jul 21
|
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
|
|
Jul 21
|
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
|
|
Jul 21
|
Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer
|
|
Jul 21
|
Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
|
|
Jul 21
|
BMS’ Phase III trial of Reblozyl misses primary endpoint
|
|
Jul 19
|
Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025
|
|
Jul 18
|
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT
|
|
Jul 18
|
Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program
|
|
Jul 18
|
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial
|
|
Jul 18
|
With 82% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing
|
|
Jul 18
|
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
|
|
Jul 17
|
Stocks to Watch Recap: TSMC, United Airlines, GE Aerospace, Lucid
|
|
Jul 17
|
GSK stock falls after FDA panel rejects blood cancer drug Blenrep
|
|
Jul 17
|
Ryan Richardson Departs BioNTech (BNTX), A Pillar In US$1 Billion Capital Raises
|